CHMP publishes highlights of its May meeting

The Committee for Medicinal Products for Human Use (CHMP) has published the highlights of its most recent meeting held on 15-18 May 2017.

Eleven medicines were recommended for approval by the committee, including one advanced therapy medicine and four biosimilars.

Negative opinions were adopted on three new medicines and in addition, one marketing authorisation application was withdawn.

Click here to see the summary of recommendations with a full list of approvals, opinions and withdrawals.